Bednárová V, Hrusková Z, Motán V, Neprasová M
Klinika 1. Lékafské fakulty UK a VFN Praha.
Vnitr Lek. 2011 Jul-Aug;57(7-8):635-9.
Three methods can be used to treat chronic renal failure - haemodialysis, peritoneal dialysis and renal transplantation (from a living donor or transplantation of a cadaver kidney). In 2009, 5,763 patients were treated with haemodialysis in the Czech Republic, while peritoneal dialysis was used in just 8% (458) of patients. This low number of peritoneal dialyses may be due to the still high number of chronic renal failure patients who come to dialysis centres "offthe street". Following acute initiation of haemodialysis, these patients are usually retained on haemodialysis. Poor awareness of peritoneal dialysis among patients as well as health care professionals is another reason for the low number of peritoneal dialysis patients. Peritoneal dialysis is suitable for home treatment. Peritoneum serves as the dialysis membrane, peritoneal cavity is filled with dialysis solution and the metabolism waste products and water are excreted into this solution. A base to correct metabolic acidosis then passes from dialysis solution into the body. Permanent catheter is inserted into the abdominal cavity to enable infusion of the dialysis solution. The dialysis is continual and this ensures stability of the inner environment and thus most closely resembles own kidney function. The advantages of peritoneal dialysis include longer preservation of residual renal function, inner environment stability and no need for venous access. Peritoneal dialysis is associated with a lower risk of infections. Peritoneal dialysis is contraindicated in patients after an extensive intraabdominal surgery and in patients with a stoma. Peritoneal damage is a serious complication of peritoneal dialysis; the risk increases with the treatment duration and thus peritoneal dialysis is not a long-term treatment choice. With the traditional CAPD (continual ambulatory peritoneal dialysis), the patient performs an exchange ofdialysis solution him/herself4 to 5 times a day. With APD (automated peritoneal dialysis) a machine performs dialysis solution exchanges, dialysis is performed at night and the patient may engage in other activities during a day. From the perspective of log-term survival of patients with chronic renal failure, peritoneal dialysis appears to be the method of choice. The patient is first treated with peritoneal dialysis and subsequently receives a transplant. Should the renal allograft be rejected, the patient returns to the dialysis programme, either peritoneal or haemodialysis. Patients should be provided with true and objective information about their disease and be informed about all treatment options for chronic renal failure. The choice of method has to be tailored to the overall health status of the patient as well as his/her lifestyle.
治疗慢性肾衰竭有三种方法——血液透析、腹膜透析和肾移植(来自活体供体或尸体肾移植)。2009年,捷克共和国有5763名患者接受血液透析治疗,而仅8%(458名)的患者使用腹膜透析。腹膜透析患者数量较少可能是因为仍有大量慢性肾衰竭患者“直接”来到透析中心。在急性开始血液透析后,这些患者通常会继续接受血液透析治疗。患者以及医护人员对腹膜透析的认知不足是腹膜透析患者数量较少的另一个原因。腹膜透析适合在家中治疗。腹膜作为透析膜,腹膜腔内充满透析液,代谢废物和水分被排泄到该溶液中。然后,用于纠正代谢性酸中毒的碱从透析液进入体内。将永久性导管插入腹腔以注入透析液。透析是持续进行的,这确保了内环境的稳定,因此最接近自身肾脏功能。腹膜透析的优点包括残余肾功能保存时间更长、内环境稳定且无需静脉通路。腹膜透析感染风险较低。腹膜透析在广泛的腹部手术后患者和有造口的患者中是禁忌的。腹膜损伤是腹膜透析的严重并发症;风险随着治疗时间的延长而增加,因此腹膜透析不是长期治疗选择。采用传统的持续非卧床腹膜透析(CAPD)时,患者自己每天进行4至5次透析液交换。采用自动化腹膜透析(APD)时,机器进行透析液交换,透析在夜间进行,患者白天可以从事其他活动。从慢性肾衰竭患者长期生存的角度来看,腹膜透析似乎是首选方法。患者首先接受腹膜透析治疗,随后接受移植。如果肾移植被排斥,患者可返回透析方案,可选择腹膜透析或血液透析。应向患者提供关于其疾病的真实客观信息,并告知他们慢性肾衰竭的所有治疗选择。治疗方法的选择必须根据患者的整体健康状况及其生活方式进行调整。